UNIVERSITY VISON

The Premier University in historic Cavite

recognized for excellence in the
development of globally competitive and
morally upright individuals.

UNIVERSITY MISSION

Republic of the Philippines

CAVITE STATE UNIVERSITY

(CvSU)

Cavite State University shall provide excellent,

equitable and relevant educational opportunities
in the arts, science and technology through
quality instruction and relevant research and
development activities. It shall produce
professional, skilled and morally upright
individuals for global competitiveness.

Don Severino Delas Alas Campus

Indang, Cavite

NCP

Name of Patient (Initial): E.D

Date of Admission: July 23, 2013

Age: 54 year old

type 2
Sex: Female

Drugs

Generic
Name :
Clonidine
Brand Name:
Catapres
Classification:
Antihyperten
sive
Dosage:
Route:
Sublingual

Diagnosis: CKD stage 5 with hypertension, DM

Date Medication started: July 23,2013

Mechanis
Indication
Contraindication
m of
Action
Unknown.
To reduce
Contraindicated
Thought to
thrombot
in patients
stimulate
ic event
hypersensitive
alpha2
in
to drug or its
receptor
patients
components
and inhibit
with
and in those
the central
atheroscl
with pathologic
vasomotor
erosis
bleeding (such
centers,
documen
as peptic ulcer
decreasin
ted by
or intracranial
g
recent
hemorrhage).

Use cautiously
sympathet
stroke,
in patients at
ic outflow
MI, or
risk for
to the
periphera
increased
heart,
l arterial

Effects

Side effects: - May

decrease platelet
count.
Adverse effect:
- Drowsiness,
dizziness,
sedation,
weakness,
fatigue, malaise,
agitation,
depression.
- Bradycardia,
severe rebound
hypertension,

Nursing
Responsibilities
Discuss
The
adverse
effect.
Make
sure that
client
stay the
medicine
under her
tongue
and
instruct
not to
swallow
it.

Frequency:
PRN
Form: Tablet
Color: White

kidneys,
and
peripheral
vasculatur
es,
lowering
vascular
resistance,
blood
pressure
and heart
rate.

disease.
To reduce
thrombot
ic events
in
patients
with
acute
coronary
syndrom
e
STsegment
elevation
acute MI
Loading
dose
regimen
in patient
undergoi
ng
coronary
stent
placeme
nt

bleeding from
trauma,
surgery, or
other
pathologic
conditions and
in those with or
renal or hepatic
impairment.

orthostatic
hypotension.
Constipation, dry
mouth, nausea,
vomiting,
anorexia.
Urine retention,
impotence.
Weight gain
Pruritus,
dermatitis with
transdermal
patch, rash.
Loss of libido.

Monitor
blood
pressure
and pulse
rate
frequently
.
Observe
patient
for
tolerance
to drugs
therapeut
ic effects,
which
may
require
increased
dosage.